ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2440

Using Patient-Relevant Variables to Describe the Disease Course in Children with Juvenile Idiopathic Arthritis

Jaime Guzman1, Andrew Henrey2, Thomas Loughin2, Roberta Berard3, Natalie Shiff4, Roman Jurencak5, Susanne Benseler6, Lori B. Tucker7 and ReACCh-Out Investigators, 1Rheumatology, Division of Rheumatology, BC Children's Hospital, Vancouver, BC, Canada, 2Statistics and Actuarial Science, Simon Fraser University, Burnaby, BC, Canada, 3Children's Hospital of Western Ontario, London, ON, Canada, 4Pediatric Rheumatology, University of Saskatchewan, Saskatoon, SK, Canada, 5University of Ottawa, Ottawa, ON, Canada, 6Alberta Children's Hospital Research Institute/University of Calgary, Calgary, AB, Canada, 7Rheumatology, BC Children's Hospital, Vancouver, BC, Canada

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Clinical research, Disease Sub-phenotyping, Juvenile Arthritis, patient outcomes and quality of life

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 10, 2015

Title: Pediatric Rheumatology - Clinical and Therapeutic Aspects Posters (ACR): Imaging and Novel Clinical Interventions

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: To define distinct disease course groups among children with Juvenile Idiopathic Arthritis (JIA) based on observed changes in quality of life, pain, medication requirements, medication side-effects and active joint counts (AJC) during the first 5 years of the disease. These variables were prioritized by patients, parents and clinicians in a previous study.

Methods: We used data from the Research in Arthritis in Canadian Children emphasizing Outcomes (ReACCh-Out) prospective inception cohort. We included 618 children newly diagnosed with JIA between 2005 and 2010 with information for at least 6 of 8 study visits within the first 5 years after diagnosis. Health-related quality of life and pain were measured with 10 cm visual analogue scales. Each current medication was given a weight and weights were added to obtain a medication requirements score. Medication side effects were reported using the Juvenile Arthritis Quality of Life Questionnaire and were weighted according to how frequently they were experienced by the child to obtain a side-effects score. AJC were reported by the attending pediatric rheumatologist. We grouped patients by course using multivariable cluster analysis and K-means clustering. Silhouette coefficients, R-Square statistics and clinical judgment were used to select the ideal number of clusters. The frequency of each disease course was described by JIA category.

Results: Four clusters provided the best discrimination: 1) Mild (43.0% of children)-almost normal quality of life throughout the disease course with initial mild pain and low AJC requiring minimal treatment, followed by normalization; 2) Moderate (33.7%)-moderate initial impact on quality of life and mild to moderate pain and AJC, followed by normalization; 3) Severe Controlled (11.6%)-moderate initial impact on quality of life and moderate pain levels with high AJC requiring aggressive treatment, followed by normalization; 4) Severe Persisting (11.6%)-persisting mayor impact on quality of life and moderate pain with moderate decreasing AJC, but ongoing treatment needs and side-effects. Children with oligoarthritis most often followed a Mild course. Almost half the children with RF negative polyarthritis, systemic and psoriatic JIA followed a Moderate course. Children with RF positive polyarthritis most often followed a Severe Controlled course. The Severe Persisting course was observed in all JIA categories but it was infrequent in systemic JIA and oligoarthritis.

Table: Proportion of children in each JIA category stratified by disease course cluster

JIA Category

Mild

Moderate

Severe Controlled

Severe Persisting

Oligoarthritis (n=228)

68.4

24.6 

0.9

6.1

RF-negative polyarthritis (n=130)

21.5

46.9 

17.7

13.8

Enthesitis-related (n=81)

37.0

29.6 

14.8

18.5

Systemic (n=47)

23.4

48.9

25.5

2.1

Psoriatic (n=38)

36.8

47.4 

2.6

13.2

RF-positive polyarthritis (n=26)

3.8

23.1 

61.5

11.5

Undifferentiated (n=68)

38.2

29.4 

8.8

23.5

Conclusion: Using patient-relevant variables the course of JIA can be described by four disease course groups with two of them reflecting a severe disease course, one that responded to treatment despite severe initial presentation and one with persisting impact on quality of life and pain despite moderate decreasing AJC. JIA category alone does not predict disease course.


Disclosure: J. Guzman, None; A. Henrey, None; T. Loughin, None; R. Berard, None; N. Shiff, None; R. Jurencak, None; S. Benseler, None; L. B. Tucker, None.

To cite this abstract in AMA style:

Guzman J, Henrey A, Loughin T, Berard R, Shiff N, Jurencak R, Benseler S, Tucker LB. Using Patient-Relevant Variables to Describe the Disease Course in Children with Juvenile Idiopathic Arthritis [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/using-patient-relevant-variables-to-describe-the-disease-course-in-children-with-juvenile-idiopathic-arthritis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/using-patient-relevant-variables-to-describe-the-disease-course-in-children-with-juvenile-idiopathic-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology